Emerging treatment for chronic migraine and refractory chronic migraine

Bibliography

• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45:S3-13
   Google Scholar
• Blumenfeld AM, Varon SF, Wilcox TK, Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-15
   PubMed Web of Science ®Google Scholar
• Bigal ME, Sheftell FD, Rapoport AM, Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002;42:575-81
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol 2000;13:277-83
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Schneeweiss S, Kurth T, Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004;62:788-90
   PubMed Web of Science ®Google Scholar
• Natoli J, Manack A, Dean B, Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599-609
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Reed M, Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559-66
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24:S9-160
   PubMedGoogle Scholar
• Headache Classification Committee, Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-6
   PubMed Web of Science ®Google Scholar
• Levin M. Refractory headache: classification and nomenclature. Headache 2008;48:783-90
   PubMed Web of Science ®Google Scholar
• Schulman EA, Lake AE III, Goadsby P, Defining refractory migraine and refractory chronic migraine: proposed criteria. Headache 2008;48:778-82
   PubMed Web of Science ®Google Scholar
• Robbins L. Refractory chronic migraine: long-term follow-up using a refractory rating scale. J Headache Pain 2012;13:225-9
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Olesen J, Bousser MG, International Headache Society. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)–revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005;25:460-5
   PubMed Web of Science ®Google Scholar
• Allena M, Katsarava Z, Nappi G; COMOESTAS Consortium. From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. J Headache Pain 2009;10:71-6
   PubMed Web of Science ®Google Scholar
• Rossi P, Jensen R, Nappi G, COMOESTAS Consortium. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain 2009;10:407-17
   PubMed Web of Science ®Google Scholar
• Hagen K, Jensen R, Bøe MG, Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain 2010;11:373-7
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• Antonaci F, Dumitrache C, De Cillis I, A review of current European guidelines for migraine. J Headache Pain 2010;11:13-19
   PubMed Web of Science ®Google Scholar
• Schulman EA, Lee Peterlin B, Lake AE III, Defining Refractory Migraine: results of the RHSIS Survey of American Headache Society Members. Headache 2009;49(4):509-18
   PubMed Web of Science ®Google Scholar
• Irimia P, Palma J-A, Fernandez-Torron R, Martinez-Vila E. Refractory migraine in a headache clinic population. BMC Neurol 2011;11:94
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Goadsby PJ, Chronic migraine–classification, characteristics and treatment. Nat Rev Neurol 2012;14:8(3):162-71
   Google Scholar
• Diener HC, Bussone G, Van Oene JC, Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27(7):814-23
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Dodick DW, Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47(2):170-80
   PubMed Web of Science ®Google Scholar
• Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998;38:468-71
   PubMed Web of Science ®Google Scholar
• Binder WJ, Brin MF, Blitzer A, Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669-76
   PubMed Web of Science ®Google Scholar
• Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003;4:146-51
   Google Scholar
• Shuhendler AJ, Lee S, Siu M, Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009;29:784-91
   PubMed Web of Science ®Google Scholar
• Aurora SK, Gawel M, Brandes JL, Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47:486-99
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Gobel H, Jensen R, Botulinum toxin type A in the prophylactic treatment of chronic tensiontype headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006;26:790-800
   PubMed Web of Science ®Google Scholar
• Padberg M, de Bruijn SF, de Haan RJ, Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004;24:675-80
   PubMed Web of Science ®Google Scholar
• Schmitt WJ, Slowey E, Fravi N, Effect of botulinum toxin A injections in the treatment of chronic tensiontype headache: a double-blind, placebo-controlled trial. Headache 2001;41:658-64
   PubMed Web of Science ®Google Scholar
• Rozen D, Sharma J. Treatment of tension-type headache with botox: a review of the literature. Mt Sinai J Med 2006;73:493-8
   PubMed Web of Science ®Google Scholar
• Naumann M, So Y, Argoff CE, for the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1707-14
   PubMed Web of Science ®Google Scholar
• Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004;24:60-5
   PubMed Web of Science ®Google Scholar
• Mathew NT, Frishberg BM, Gawel M, Botulinum toxin type A. BOTOX®) for the prophylactic treatment of chronic daily headache: A randomized, doubleblind, placebo-controlled trial. Headache 2005;45:293-307
   PubMed Web of Science ®Google Scholar
• Dodick DW, Mauskop A, Elkind AH, Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005;45:315-24
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008;48:194-200
   PubMed Web of Science ®Google Scholar
• Autret A, Valade D, Debiais S. Placebo and other psychological interactions in headache treatment. J Headache Pain 2012;13:191-8
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Mattsson P, Zwart JA, Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003;23:487-90
   PubMed Web of Science ®Google Scholar
• Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientifi c and ethical rationale for continued use of placebo controls. Cephalalgia 2005;25:124-31
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Curr Treat Options Neurol 2009;11:18-23
   PubMed Web of Science ®Google Scholar
• Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road?. Cephalalgia 2006;26:769-71
   PubMed Web of Science ®Google Scholar
• AteŞ Y. Botulinum toxin for the treatment of headaches: a review of current practices and evidence-based data. Agri 2006;18:5-11
   PubMedGoogle Scholar
• Gupta VK. Botulinum toxin—a treatment for migraine? A systematic review. Pain Med 2006;7:3869-4
   Google Scholar
• Pakalnis A, Couch J. Headache therapy with botulinum toxin—form over substance. Arch Neurol 2008;65:149-51
   PubMed Web of Science ®Google Scholar
• Roach ES. Questioning botulinum toxin for headache—reality or illusion. Arch Neurol 2008;65:151-2
   PubMed Web of Science ®Google Scholar
• Farinelli I, Coloprisco G, De Filippis S, Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 2006;7:407-12
   PubMedGoogle Scholar
• Oterino A, Ramón C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain 2011;12:235-8
   PubMed Web of Science ®Google Scholar
• Bittar RG, Teddy PJ. Peripheral neuromodulation for pain. J Clin Neurosci 2009;16(10):1259-61
   PubMed Web of Science ®Google Scholar
• Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation 1999;2(3):217-21
   PubMed Web of Science ®Google Scholar
• Lambru G, Matharu MS. Occipital nerve stimulation in primary headache syndromes. Ther Adv Neurol Disord 2012;5(1):57-67
   PubMedGoogle Scholar
• Ellens DJ, Levy RM. Peripheral neuromodulation for migraine headache. Prog Neurol Surg 2011;24:109-17
   PubMedGoogle Scholar
• Jenkins B, Tepper SJ. Neurostimulation for Primary Headache Disorders, Part 1: pathophysiology and Anatomy, History of Neuromodulation in Headache Treatment, and Review of Peripheral Neuromodulation in Primary Headaches. Headache 2011;51(8):1254-66
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse RE, PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-14
   PubMed Web of Science ®Google Scholar
• Lipton RB, Varon SF, Grosberg B, OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77:1465-72
   PubMed Web of Science ®Google Scholar
• Mauskop A. The use of botulinum toxin in the treatment of headaches. Pain Physician 2004;7:377-87
   PubMedGoogle Scholar
• Olesen J, Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet 2010;376:1825-6
   PubMed Web of Science ®Google Scholar
• Russell MB. Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 2011;12:135-6
   PubMed Web of Science ®Google Scholar
• Gerwin R. Treatment of chronic migraine headache with onabotulinumtoxinA. Curr Pain Headache Rep 2011;15:336-8
   PubMed Web of Science ®Google Scholar
• Aurora S, Diener HC, Dodick D; PREEMPT Chronic Migraine Study Group. Reply: clinical trials on onabotulinumtoxinA for the treatment of chronic migraine. J Headache Pain 2011;12:137-8
   PubMed Web of Science ®Google Scholar
• Silberstein S, Tfelt-Hansen P, Dodick DW, Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484-95
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not?. J Headache Pain 2011;12:593-601
   PubMed Web of Science ®Google Scholar
• Blumenfeld A, Silberstein SD, Dodick DW, Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010;50:1406-18
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008;48:210-20
   PubMed Web of Science ®Google Scholar
• Magalhaes E, Menezes C, Cardeal M, Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010;112:463-6
   PubMed Web of Science ®Google Scholar
• Mathew NT, Jaffri SFA. A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study. Headache 2009;49:1466-78
   PubMed Web of Science ®Google Scholar
• Cady RK, Schreiber CP, Porter JA, A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011;51:21-32
   PubMed Web of Science ®Google Scholar
• Saper JR, Dodick DW, Silberstein SD, Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011;31(3):271-85
   PubMed Web of Science ®Google Scholar
• Lipton R, Goadsby P, Cady R, P047 - PRISM study: occipital nerve stimulation for treatment-refractory migraine. Cephalalgia 2009;29(Suppl 1):1-166
   Google Scholar
• Silberstein S, Dodick D, Saper J, PSI - 227. The safety and efficacy of occipital nerve stimulation for the management of chronic migraine. Cephalalgia 2011;31(Suppl 1):1-216
   PubMedGoogle Scholar
• Aurora SK, Dodick DW, Turkel CC, OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30(7):793-803
   PubMed Web of Science ®Google Scholar
• Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 2008;48:900-13
   PubMed Web of Science ®Google Scholar
• Sandrini G, Perrotta A, Tassorelli C, Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain 2011;12:427-33
   PubMed Web of Science ®Google Scholar
• Eross EJ, Gladstone JP, Lewis S, Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005;45:308-14
   PubMed Web of Science ®Google Scholar
• Christie SN, Giammarco R, Gawel M, Botulinum toxin type A and acute drug costs in migraine with triptan overuse. Can J Neurol Sci 2010;37:588-94
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Charbit AR, Andreou AP, Neurobiology of migraine. Neuroscience 2009;161(2):327-41
   PubMed Web of Science ®Google Scholar
• Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 2003;126(Pt 8):1801-13
   PubMed Web of Science ®Google Scholar
• Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 2002;125(Pt 7):1496-509
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Akerman S. The trigeminovascular system does not require a peripheral sensory input to be activated - migraine is a central disorder. Cephalalgia 2012;32:3-5
   PubMed Web of Science ®Google Scholar
• Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12(10):570-84
   PubMed Web of Science ®Google Scholar
• Meehan AL, Yang X, McAdams BD, A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol 2011;106:1227-39
   PubMed Web of Science ®Google Scholar
• Beran RG, Spira PJ. Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]). Cephalalgia 2011;31:530-6
   PubMed Web of Science ®Google Scholar
• Krüger S, Bräunig P. Intravenous valproic acid in the treatment of severe catatonia. J Neuropsychiatry Clin Neurosci 2001;13:303-4
   PubMed Web of Science ®Google Scholar
• Afshari D, Rafizadeh S, Rezaei M. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci 2012;122:60-8
   PubMed Web of Science ®Google Scholar
• Errington AC, Stöhr T, Heers C, The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Neurofarmacology 2006;50:1016-29
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Álvarez AM, Sagarra-Mur D, Jiménez-Corral C. Lacosamide, new antiepileptic with broad perspectives. Neurologia 2011;26:568-9
   PubMed Web of Science ®Google Scholar
• Halasz P, Kälviainen R, Marzurkiewicz-Beldzinska M, Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Olesen J. The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012;13:271-5
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Diener HC, Géraud G, Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13
   PubMed Web of Science ®Google Scholar
• Peroutka SJ. 2010: year in review. Headache 2011;51:181-7
   Google Scholar
• Colman SS, Brod MI, Krishnamurthy A, Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001;23:127-45
   PubMed Web of Science ®Google Scholar
• Taylor FR. Migraine headache: options for acute treatment. Curr Neurol Neurosci Rep 2005;5:86-92
   PubMedGoogle Scholar
• Yang ZY, Le Y, Hu TT, Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm Res 2008;25:2012-18
   PubMed Web of Science ®Google Scholar
• Available from: www.optinose.com/clinical-trials/target-clinical-trial-for-migraine
   Google Scholar
• Frampton JE. Needle-free subcutaneous sumatriptan: in the acute treatment of migraine attacks or cluster headache episodes. CNS Drugs 2011;1;25:983-94
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, Simmaco M, CGRP receptor antagonists: an expanding drug class for acute migraine?. Expert Opin Investig Drugs 2012;21:807-18
   PubMed Web of Science ®Google Scholar
• Coleman PJ, Schreier JD, Cox CD, Discovery of [(2R,5R)-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone(MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. Chem Med Chem 2012;7:415-24
   Google Scholar
• Available from: http://www.lupinworld.com/
   Google Scholar
• Sang CN, Ramadan NM, Wallihan RG, LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24(7):596-602
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Tronvik E, Hagen K. New drugs for migraine. J Headache Pain 2009;10:395-406
   PubMed Web of Science ®Google Scholar
• Passie T. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008;14:295-314
   PubMed Web of Science ®Google Scholar
• Karst M, Halpern JH, Bernateck M, The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia 2010;30:1140-4
   PubMed Web of Science ®Google Scholar
• Magis D, Bruno M-A, Fumal A, Central modulation in cluster headache patients treated with occipital nerve stimulation: an FDG-PET study. BMC Neurol 2011;11:25
   PubMed Web of Science ®Google Scholar
• Dario A, Scamoni C, Peron S, Tomei G, A case of post-traumatic cervicogenic headache treated by cervical cord stimulation. J Headache Pain; 2005;6:473
   Google Scholar
• Reed K, Black S, Banta C II, Will K. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 2010;30:260-71
   PubMed Web of Science ®Google Scholar